CSV May 16, 2022 through May 16, 2024 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort descending	Description

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort descending	Description
CEFADROXIL CAPSULES	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*First Supplement to USP37–NF32*	6604	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 2 of USP Cefadroxil Related Compound I RS: Change (6*R*,7*R*)-7-[(*R*)-2-Amino-2-(4-hydroxyphenyl) acetamido]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid monohydrate. to: (6*R*,7*R*)-7-[(*R*)-2-Amino-2-(4-hydroxyphenyl) acetamido]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-3-ene-2-carboxylic acid.
CEFUROXIME FOR INJECTION	*Constituted solution*	*USP37–NF32*	2246	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 3: Change meets the requirements

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort descending	Description
								for *Constituted Solutions* under *Labeling* under *Injections <1>*. to: meets the requirements for *Constituted Solutions* under *Injections <1>*.
ESCITALOPRAM ORAL SOLUTION	IMPURITIES/*Organic Impurities*	*USP37–NF32*	2580	26-Sep-2014	1-Oct-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Row 6 of Column 1 of *Table 3*: Change Desfluorocitalopram[f] to: Desfluorocitalopram[f,c]
STERILE WATER FOR INHALATION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP37–NF32*	5174	26-Sep-2014	1-Oct-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Add: USP 1,4-Benzoquinone RS AND USP Sucrose RS
LEVOTHYROXINE SODIUM TABLETS	IMPURITIES/*Organic Impurities/Proce*	*USP37–NF32*	3548	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 1 of *Acceptance criteria*: Change NMT 2.0% of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort descending	Description
	dure: Limit of Liothyronine Sodium							liothyronine to: NMT 2.0% of liothyronine sodium
DEXCHLORPHENIRAMINE MALEATE	IMPURITIES/*Organic Impurities*	*First Supplement to USP37–NF32*	6626	26-Sep-2014	1-Oct-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 1 of *Standard solution*: 2.2 ?g/mL of USP Dexchlorpheniramine Maleate RS in *Diluent*, to: 2.8 ?g/mL of USP Dexchlorpheniramine Maleate RS in *Diluent*,
INSULIN ASPART	IDENTIFICATION/*B. Physicochemical Analytical Procedures for Insulins, Peptide Mapping <121.1>/Chromatographic system*	*First Supplement to USP37–NF32*	6647	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 1 of *Column*: Change 4.0-mm × 25-cm; 5-µm packing L7 to: 4.6-mm × 10-cm; 3-?m packing L1
CHLORDIAZEP	*Constituted*	*USP37–NF32*	2290	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First*	Line 1: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort descending	Description
OXIDE HYDRO CHLORIDE FOR INJECTION	*solution*						*Supplement to USP38–NF33*	At the time of use, it meets the requirements for *Constituted Solutions* under *Labeling* under *Injections <1>*. to: At the time of use, it meets the requirements for *Constituted Solutions* under *Injections <1>*.
DIDANOSINE DELAYED-RELEASE CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>/Analysis*	*USP37–NF32*	2603	26-Sep-2014	1-Oct-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 11 of the variable definition list: Change C_S = concentration of didanosine in the *Standard solution* (mg/mL) to: C_S = concentration of USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort descending	Description
								Didanosine Related Compound A RS in the *Standard solution* for the *Acid stage* or concentration of USP Didanosine RS in the *Standard solution* for the *Buffer stage* (mg/mL)
STERILE WATER FOR INJECTION	CHEMICAL INFORMATION	*USP37–NF32*	5175	26-Sep-2014	1-Oct-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Add the chemical formula and molecular weight: H_2O 18.02
MITOTANE TABLETS	*Assay*	*USP37–NF32*	3858	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 1 of *Procedure*: Change Proceed as directed in the *Assay* under *Mitotane*, beginning with “Concomitantly determine the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort descending	Description
								absorbances of both solutions." to: Concomitantly determine the absorbances of the *Assay preparation* and the *Standard preparation* in 1-cm cells at the wavelength of maximum absorbance at about 268 nm, with a suitable spectrophotometer, using methanol as the blank. Calculate the quantity, in mg, of $C_{14}H_{10}Cl_4$ in the portion of Tablets taken by the formula: $0.5C(A_U/A_S)$ in which C is the concentration,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort descending	Description
								in mg/mL, of USP Mitotane RS in the *Standard preparation*, and A_U and A_S are the absorbances of the *Assay preparation* and the *Standard preparation*, respectively.
DACARBAZINE FOR INJECTION	IMPURITIES/*Limit of 2-Azahypoxanthine*	*Second Supplement to USP37–NF32*	Online	26-Sep-2014	1-Oct-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 2 of *Analysis*: Change 2-azahypoxanthine monohydrate to: 2-azahypoxanthine
SUFENTANIL CITRATE	ASSAY/*Procedure/System suitability/Suitability requirements*	*First Supplement to USP37–NF32*	6701	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 1 of *Relative standard deviation*: Change NMT 0.7% to: NMT 0.73%

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort descending	Description
CLOPIDOGREL BISULFATE	ASSAY/ *Procedure*	*USP37–NF32*	2422	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 1 of *System suitability solution*: Change 25 µg/mL of USP Clopidogrel Bisulfate RS and 50 µg/mL of USP Clopidogrel Related Compound B RS to: 2.5 µg/mL of USP Clopidogrel Bisulfate RS and 5.0 µg/mL of USP Clopidogrel Related Compound B RS
DROSPIRENONE AND ETHINYL ESTRADIOL	IMPURITIES/*Organic Impuri*	*USP37–NF32*	2739	26-Sep-2014	1-Oct-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 2 of *Detector 2*: Change Monitor the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort descending	Description
TABLETS	*ties/ Chromatographic system*							signal at 344 nm between 37 and 42 min. to: Monitor the signal at 344 nm for ethinyl estradiol related compound B (typically between 37 and 42 min).
STERILE WATER FOR INJECTION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP37–NF32*	5175	26-Sep-2014	1-Oct-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Add: USP 1,4-Benzoquinone RS AND USP Sucrose RS
NALTREXONE HYDROCHLORIDE	*Assay*	*USP37–NF32*	3922	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 7 of *Procedure*: Change (377.86/341.41) $10C(r_U/r_S)$ in which 377.86 and 341.41 are the molecular weights of naltrexone hydrochloride and naltrexone

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort descending	Description
								to: (377.86/341.40)10$C(r_U/r_S)$ in which 377.86 and 341.40 are the molecular weights of naltrexone hydrochloride and naltrexone
PHARMACEUTICAL COMPOUNDING—NONSTERILE PREPARATIONS	DEFINITIONS	*USP37–NF32*	403	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 1 of *Beyond-Use Date (BUD)*: Change The date after which a compounded preparation should not to be used; to: The date after which a compounded preparation shall not be used;
TERBINAFINE HYDROCHLORIDE	IMPURITIES	*First Supplement to USP37–NF32*	6704	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Footnotes b, c, and d of *Table 2*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort descending	Description
								[b]*trans*-Isoterbinafine or (*E*)-*N*,6,6-trimethyl-*N*-(naphthalen-2-ylmethyl)hept-2-en-4-yn-1-amine. [c]*cis*-Terbinafine or (*Z*)-*N*,6,6-trimethyl-*N*-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine. [d]4-Methylterbinafine or (*E*)-*N*,6,6-trimethyl-*N*-((4-methylnaphthalen-1-yl)meth

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort descending	Description
								yl)hept-2-en-4-yn-1-amine. to: [b]*trans*-Isoterbinafine or (2*E*)-*N*, 6, 6-Trimethyl-*N*-(naphthalen-2-ylmethyl)hept-2-en-4-yn-1-amine. [c]*cis*-Terbinafine or (2*Z*)-*N*, 6, 6-Trimethyl-*N*-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine. [d] 4-Methylterbinafine or (2*E*)-*N*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort descending	Description
DOXAPRAM HYDROCHLORIDE INJECTION	ASSAY/ *Procedure*	*USP37–NF32*	2708	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	, 6, 6-Trimethyl-*N*-((4-methylnaphthalen-1-yl)methyl)hept-2-en-4-yn-1-amine. Line 7 of *Analysis*: Change R_U = peak response ratio of the doxapram to the internal standard from the *Sample solution* R_S = peak response ratio of the doxapram to the internal standard from the *Sample solution* to: R_U = peak response ratio of doxapram to the internal

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort descending	Description
								standard from the *Sample solution* R_S = peak response ratio of doxapram to the internal standard from the *Standard solution*
IRINOTECAN HYDROCHLORIDE INJECTION	IMPURITIES/*Organic Impurities*	*USP37–NF32*	3403	26-Sep-2014	1-Oct-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Row 3 of Column 1 of *Table 2*: Change Camptothecin[b] to: Camptothecin[b,d] AND Row 5 of Column 1: Change 7-Ethylcamptothecin[c] to: 7-Ethylcamptothecin[c,d] AND Add a footnote: [d]These process

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort descending	Description
								impuritiesare included in the table for identification only and are not included in the *Total impurities*.
STERILE WATER FOR IRRIGATION	CHEMICAL INFORMATION	*USP37–NF32*	5175	26-Sep-2014	1-Oct-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Add the chemical formula and molecular weight: H_2O 18.02
TICLOPIDINE HYDROCHLORIDE	IMPURITIES	*USP37–NF32*	4958	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Change *Residue on Ignition <231>* to: *Residue on Ignition <281>*
METHODS FOR THE DETERMINATION OF PARTICULATE MATTER IN INJECTIONS AND OPHTHALMIC SOLUTIONS	LIGHT OBSCURATION PARTICLE COUNT TEST/ *Instrument Standardization Tests*/*Particle Counting Accuracy—System Suitability*	*USP37–NF32*	1301	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 26 of *Method 1—MWHC Instruments*: Change P_B is the average particle count obtained from the suspension; to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort descending	Description
TERBINAFINE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*First Supplement to USP37–NF32*	6704	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	P_S is the average particle count obtained from the suspension; Line 2 of USP Terbinafine Related Compound A RS: Change *N* -Methyl-*C* -(naphthalen-1-yl)methanamine . to: *N* -Methyl-*C* -(naphthalen-1-yl)methanamine hydrochloride. AND Line 2 of USP Terbinafine Related Compound B RS: Change (2*Z*)-*N* , 6,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort descending	Description
								6-Trimethyl-*N*-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine. to: (2*Z*)-*N*,6,6-Trimethyl-*N*-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine hydrochloride. AND Line 2 of USP Terbinafine Related Compound C: Change (2*E*)-*N*,6,6-Trimethyl-*N*-(naphthalen-2-ylmethyl)hept-2-en-4-yn-1-amin

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort descending	Description
								e. to: (2*E*)-*N* , 6, 6-Tr imethyl-*N* -(naphthalen-2- ylmethyl)hept-2- en-4-yn-1-amin e hydrochloride. AND Line 2 of Terbinafine Related Compound D RS: Change (2*E*)-*N* , 6, 6-Tr imethyl-*N* -[(4-methylnaph thalen-1-yl)meth yl]hept-2-en-4-y n-1-amine. to: (2*E*)-*N* , 6,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort descending	Description
DOXEPIN HYDROCHLORIDE CAPSULES	PERFORMANCE TESTS	*USP37–NF32*	2712	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	6-Trimethyl-*N*-[(4-methylnaphthalen-1-yl)methyl]hept-2-en-4-yn-1-amine hydrochloride. Change *Uniformity of Dosage Units, Content Uniformity <905>* to: *Uniformity of Dosage Units <905>*: Meet the requirements The following procedure is used where the test for *Content Uniformity* is required. *Procedure for Content Uniformity* AND Delete a

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort descending	Description
								subsection: *Acceptance criteria:* Meet the requirements
KETOPROFEN EXTENDED-RELEASE CAPSULES	ASSAY/*Procedure*/*System suitability*/*Suitability requirements*	*USP37–NF32*	3469	26-Sep-2014	1-Oct-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 1 of *Tailing factor*: Change NLT 1.5 to: NMT 1.5
STERILE WATER FOR IRRIGATION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP37–NF32*	5175	26-Sep-2014	1-Oct-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Add: USP 1,4-Benzoquinone RS AND USP Sucrose RS
VINBLASTINE SULFATE	IDENTIFICATION/*B.*	*USP37–NF32*	5150	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 1 of *Sample*: Change 100 mg/mL in water to: 10 mg/mL in water
ALLOPURINOL	*USP Reference standards <11>*	*USP37–NF32*	1649	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 2 of USP Allopurinol Related Compound C RS: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort descending	Description
								N-(4*H*-1,2,4-Triazol-4-yl)-1*H*-pyrazole-4-carboxamide. to: 5-(4*H*-1,2,4-Triazol-4-yl)-1*H*-pyrazole-4-carboxamide.
RISPERIDONE ORAL SOLUTION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*Second Supplement to USP37–NF32*	Online	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 2 of USP Risperidone Related Compounds Mixture RS: Change Contains a mixture of the following four compounds: 98.9% of *Risperidone*. 0.5% of *Risperidone cis-N-oxide*: *cis*-3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort descending	Description
								8,9-tetrahydro-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-*N*-oxide. 0.3% of *Bicyclorisperidone*: 3-(4-Fluoro-2-hydroxyphenyl)-1-[2-(6,7,8,9-tetrahydro-2-methyl-4-oxo-4*H*-pyrido-[1,2-*a*]pyrimidin-3-yl)ethyl]-1-aza-2-azoniabicyclo[2.2.2]oct-2-ene iodide. 0.3% of *Z*-*Oxime*: (*Z*)-3-[2-[4-(2,4-Difluorophenyl)(hydroxyimino)met

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort descending	Description
								hyl]-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one. to: Contains a mixture of the following four compounds: Risperidone. Risperidone *cis*-*N*-oxide: *cis*-3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, *N*-oxide. Bicyclorisperidone: 3-(4-Fluoro-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort descending	Description
								2-hydroxyphenyl)-1-[2-(6,7,8,9-tetrahydro-2-methyl-4-oxo-4*H*-pyrido-[1,2-*a*]pyrimidin-3-yl)ethyl]-2-aza-1-azoniabicyclo[2.2.2]oct-2-ene iodide. *Z*-Oxime: (*Z*)-3-[2-[4-(2,4-Difluorophenyl)(hydroxyimino)methyl]-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one.
DULOXETINE DELAYED-RELEASE CAPSULES	IDENTIFICATION	*USP37–NF32*	2743	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Change *A. Infrared Absorption <197S>*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort descending	Description
								to: *A. Infrared Absorption <197F>*
KETOPROFEN EXTENDED-RELEASE CAPSULES	PERFORMANCE TESTS/ *Uniformity of Dosage Units <905>/System suitability/Suitability requirements*	*USP37–NF32*	3469	26-Sep-2014	1-Oct-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 1 of *Tailing factor*: Change NLT 1.5 to: NMT 1.5
PURE STEAM	CHEMICAL INFORMATION	*USP37–NF32*	5176	26-Sep-2014	1-Oct-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Add the chemical formula and molecular weight: H_2O 18.02
VITAMIN E	IDENTIFICATION/*A./Sample solutions*	*USP37–NF32*	5163	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Lines 4 and 7 of *Alpha tocopheryl acetate*: Change dilute sulfuric acid to: diluted sulfuric acid
AMIFOSTINE	ASSAY/	*USP37–NF32*	1717	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First*	Line 1 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort descending	Description
	Procedure/System suitability/Suitability requirements						*Supplement to USP38–NF33*	*Column efficiency*: Change NLT 100 to: NLT 1000
TIZANIDINE TABLETS	ASSAY/ *Procedure/System suitability*	*Second Supplement to USP37–NF32*	Online	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Change *Sample*: *Standard solution* to: *Samples*: *System suitability solution* and *Standard solution* AND Change *Resolution*: NLT 4.0 between tizanidine and tizanidine related compound C; NLT 4.0 between tizanidine and tizanidine related

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort descending	Description
								compound B *Tailing factor*: NMT 2.0 *Relative standard deviation*: NMT 2.0% to: *Resolution*: NLT 4.0 between tizanidine and tizanidine related compound C; NLT 4.0 between tizanidine and tizanidine related compound B, *System suitability solution* *Tailing factor*: NMT 2.0, *Standard solution* *Relative standard deviation*: NMT

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort descending	Description
								2.0%, *Standard solution*
ERGOTAMINE TARTRATE	*Identification*	*USP37–NF32*	2826	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 4:Change value as the principal spot of *Standard solution A*. to: values as the corresponding spots of the *Standard preparation*.
OXYBUTYNIN CHLORIDE	SPECIFIC TESTS/*Loss on Drying <731>*	*USP37–NF32*	4129	26-Sep-2014	1-Oct-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 1 of *Acceptance criteria*: Change NMT 3.0% to: NMT 3%
STERILE PURIFIED WATER	ADDITIONAL REQUIREMENTS	*USP37–NF32*	5176	26-Sep-2014	1-Oct-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Add a section: *USP Reference Standards <11>* USP 1,4-Benzoquinone RS USP Sucrose RS
GELATIN	SPECIFIC TESTS/*Sulfur Dioxide/ Analysis*	*USP37–NF32*	5995	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 5 of the variable definition list: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort descending	Description
								m = actual molarity of the *Titrant* (mol/mL) to: *m* = actual molarity of the *Titrant* (mol/L)
BUMETANIDE	IMPURITIES	*USP37–NF32*	2024	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Row 4 of Column 1 of *Table 1*: Change Paroxetine butyl 3-(butylamino)-4-phenoxy-5-sulfamoylbenzoate to: Butyl 3-(butylamino)-4-phenoxy-5-sulfamoylbenzoate
ROPINIROLE HYDROCHLORIDE	IMPURITIES/*Organic Impurities, Procedure 1/System suitability/Suitability requirements*	*Revision Bulletin (Official May 01, 2014)*	Online	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 1 of *Tailing factor*: Change NLT 2.0 for the ropinirole peak to: NMT 2.0 for the ropinirole peak
FLAVOXATE HYDROCHLORI	IMPURITIES	*USP37–NF32*	2988	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to*	Row 3 of Column 1 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort descending	Description
DE							*USP38–NF33*	*Impurity Table 1*: Change Flavoxate related compound A[a,*] to: Flavoxate related compound A[a] AND Row 4 of Column 1 of *Impurity Table 1*: Change Flavoxate related compound B[b,*] to: Flavoxate related compound B[b] AND Row 5 of Column 1 of *Impurity Table 1*: Change Flavoxate related compound C[c,*] to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort descending	Description
								Flavoxate related compound C[c] AND Delete footnote *
PSEUDOEPHEDRINE HYDRO CHLORIDE	ASSAY/ *Procedure*	*USP37–NF32*	4481	26-Sep-2014	1-Oct-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 2 of *System suitability solution*: Change 0.02 mg/mL of USP Ephedrine Sulfate RS to: 0.002 mg/mL of USP Ephedrine Sulfate RS
CELLACEFATE	ASSAY/*Content of Acetyl*	*USP37–NF32*	5919	26-Sep-2014	1-Oct-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 12 of *Analysis*: Result = {[(*P* ? 0.5182 × *B*)/(100 ? *B*)] ? (0.5772 × *C*)} × 100 to: Result = 100 × [*P* ? (0.5182 × *B*)]/(100 ? *B*) ?

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort descending	Description
								(0.5772 × *C*)
VITAMIN E ASSAY	ASSAY/ *Procedure 4/ Chromatographic system*	*First Supplement to USP37–NF32*	6338	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 1 of *Flow rate*: Change 1.5 mL/min to: 1 mL/min
CEFAZOLIN INJECTION	*Assay*	*USP37–NF32*	2190	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Change *pH 3.6 Buffer*, *pH 7.0 Buffer*, *Mobile phase*, *Internal standard solution*, *Standard preparation*, and *Chromatographic system*—Prepare as directed in the *Assay* under *Cefazolin*. to: *pH 3.6 Buffer*—Dissolve 0.900 g of anhydrous dibasic sodium phosphate and 1.298 g of citric

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort descending	Description
								acid monohydrate in water to make 1000 mL. *pH 7.0 Buffer*—Dissolve 5.68 g of anhydrous dibasic sodium phosphate and 3.63 g of monobasic potassium phosphate in water to make 1000 mL. *Mobile phase*—Prepare a suitable mixture of *pH 3.6 Buffer* and acetonitrile (9:1). Pass through a membrane filter having a 10-?m or finer porosity, and degas. Make adjustments if

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort descending	Description
								necessary (see *System Suitability* under *Chromatography <621>*). *Internal standard solution* —Transfer 750 mg of salicylic acid to a 100-mL volumetric flask, dissolve in 10 mL of methanol, dilute with *pH 7.0 Buffer* to volume, and mix. *Standard preparation* —Transfer about 25 mg of USP Cefazolin RS, accurately weighed, to a 25-mL volumetric flask, dissolve in and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort descending	Description
								dilute with *pH 7.0 Buffer* to volume, and mix. Transfer 5.0 mL of this solution to a 100-mL volumetric flask, add 5.0 mL of *Internal standard solution*, dilute with *pH 7.0 Buffer* to volume, and mix. *Chromatographic system* (see *Chromatography <621>*)—The liquid chromatograph is equipped with a 254-nm detector and a 4.0-mm × 30-cm column that contains 10-?m packing L1. The flow

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort descending	Description
								rate is about 2 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*. The relative retention times are about 0.7 for salicylic acid and 1.0 for cefazolin; the resolution, *R*, between the analyte and internal standard peaks is not less than 4.0; the column efficiency is not less than 1500 theoretical plates; the tailing factor is not more than 1.5; and the relative

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort descending	Description
								standard deviation for replicate injections is not more than 2.0%. AND Change *Procedure*—Proceed as directed for *Procedure* in the *Assay* under *Cefazolin*. Calculate the quantity, in mg, of cefazolin ($C_{14}H_{14}N_8O_4S_3$) in each mL of the Injection taken by the formula: $(1000C / V)(R_U / R_S)$ in which V is the volume, in mL, of Injection taken, and the other terms are as defined

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort descending	Description
								therein. to: *Proce dure* —Separately inject equal volumes (about 10 ?L) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity, in mg, of cefazolin ($C_{14}H_{14}N_8O_4S_3$) in each mL of Injection taken by the formula: $(1000C / V)(R_U / R_S)$ in which *C* is

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort descending	Description
								the concentration, in mg per mL, of USP Cefazolin RS, calculated on the anhydrous basis, in the *Standard preparation*; *V* is the volume, in mL, of Injection taken; and R_U and R_S are the peak response ratios of cefazolin to the internal standard obtained from the *Assay preparation* and the *Standard preparation*, respectively.
BETAMETHASONE SODIUM PHOSPHATE	IM PURITIES/*Limit of Free Betamethasone*	*USP37–NF32*	1965	26-Sep-2014	1-Oct-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 1 of *Sample stock solution*: Change 1.0 mg/mL of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort descending	Description
								Betamethasone Sodium Phosphate in water to: 1.0 mg/mL of Betamethasone Sodium Phosphate in water, prepared as follows. Dissolve 25.0 mg of Betamethasone Sodium Phosphate in water to make 25.0 mL.
LEFLUNOMIDE	IMPURITIES/*Organic Impurities/Procedure 2*	*USP37–NF32*	3502	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 3 of *Analysis*: Change [Note—Disregard any peak with an area less than the leflunomide peak from the *System suitability solution*.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication Sort descending	Description
								to: [Note—Disregard any peak with an area less than the leflunomide peak from the *Sensitivity solution*.

Pagination

- First page « First
- Previous page ‹ Previous
- Page 1
- Page 2
- Page 3
- Current page 4
- Page 5
- Page 6
- Page 7
- Page 8
- Page 9
- …
- Next page Next ›
- Last page Last »